Literature DB >> 14513042

Many and multiple myeloma(s).

R Fonseca1.   

Abstract

Entities:  

Mesh：

Year:  2003        PMID： 14513042     DOI： 10.1038/sj.leu.2403090

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  9 in total

1.  Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone.

Authors:  Shaji K Kumar; Hajime Uno; Susanna J Jacobus; Scott A Van Wier; Greg J Ahmann; Kimberly J Henderson; Natalie S Callander; Jessica L Haug; David S Siegel; Philip R Greipp; Rafael Fonseca; S Vincent Rajkumar
Journal:  Blood       Date:  2011-08-22       Impact factor: 22.113

Review 2.  Risk Stratification in Multiple Myeloma in Indian Settings.

Authors:  Rajan Kapoor; Rajiv Kumar; A P Dubey
Journal:  Indian J Hematol Blood Transfus       Date:  2019-12-14       Impact factor: 0.900

3.  Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines.

Authors:  Shaji K Kumar; Joseph R Mikhael; Francis K Buadi; David Dingli; Angela Dispenzieri; Rafael Fonseca; Morie A Gertz; Philip R Greipp; Suzanne R Hayman; Robert A Kyle; Martha Q Lacy; John A Lust; Craig B Reeder; Vivek Roy; Stephen J Russell; Kristen E Detweiler Short; A Keith Stewart; Thomas E Witzig; Steven R Zeldenrust; Robert J Dalton; S Vincent Rajkumar; P Leif Bergsagel
Journal:  Mayo Clin Proc       Date:  2009-12       Impact factor: 7.616

Review 4.  International Myeloma Working Group molecular classification of multiple myeloma: spotlight review.

Authors:  R Fonseca; P L Bergsagel; J Drach; J Shaughnessy; N Gutierrez; A K Stewart; G Morgan; B Van Ness; M Chesi; S Minvielle; A Neri; B Barlogie; W M Kuehl; P Liebisch; F Davies; S Chen-Kiang; B G M Durie; R Carrasco; Orhan Sezer; Tony Reiman; Linda Pilarski; H Avet-Loiseau
Journal:  Leukemia       Date:  2009-10-01       Impact factor: 11.528

Review 5.  Interpretation of cytogenetic results in multiple myeloma for clinical practice.

Authors:  A M Rajan; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-10-30       Impact factor: 11.037

6.  Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study.

Authors:  Odunukwe Nkiruka Nnonyelum; Madu Jude Anazoeze; Nnodu Obigeli Eunice; Okocha Onyichide Emmanuel; Akingbola Titilola Stella; Asuquo Inyama Marcus; Balogun Modupe Taiwo; Kalejaiye Olufunto Olufela; Aneke John Chinawaeze; Joseph Aondowase Orkuma; Gwarzo Gwarzo Dalhat; Ujah Innocent Otobo
Journal:  Pan Afr Med J       Date:  2015-11-24

7.  Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.

Authors:  A J Greenberg; S Philip; A Paner; S Velinova; A Badros; R Catchatourian; R Ketterling; R A Kyle; S Kumar; C M Vachon; S V Rajkumar
Journal:  Blood Cancer J       Date:  2015-01-02       Impact factor: 11.037

8.  Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature.

Authors:  Khadega A Abuelgasim; Noha Alherz; Ayman Alhejazi; Moussab Damlaj
Journal:  J Med Case Rep       Date:  2020-04-23

Review 9.  Multiple Myeloma With Amplification of Chr1q: Therapeutic Opportunity and Challenges.

Authors:  Romanos Sklavenitis-Pistofidis; Gad Getz; Irene Ghobrial; Maria Papaioannou
Journal:  Front Oncol       Date:  2022-07-14       Impact factor: 5.738
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.